Topical treatments for atopic dermatitis (eczema) : Systematic review and network meta-analysis of randomized trials
Copyright © 2023. Published by Elsevier Inc..
BACKGROUND: Atopic dermatitis (AD) is a common skin condition with multiple topical treatment options, but uncertain comparative effects.
OBJECTIVE: We sought to systematically synthesize the benefits and harms of AD prescription topical treatments.
METHODS: For the 2023 American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma, and Immunology Joint Task Force on Practice Parameters AD guidelines, we searched MEDLINE, EMBASE, CENTRAL, CINAHL, LILACS, ICTRP, and GREAT databases to September 5, 2022, for randomized trials addressing AD topical treatments. Paired reviewers independently screened records, extracted data, and assessed risk of bias. Random-effects network meta-analyses addressed AD severity, itch, sleep, AD-related quality of life, flares, and harms. The Grading of Recommendations Assessment, Development and Evaluation approach informed certainty of evidence ratings. We classified topical corticosteroids (TCS) using 7 groups-group 1 being most potent. This review is registered in the Open Science Framework (https://osf.io/q5m6s).
RESULTS: The 219 included trials (43,123 patients) evaluated 68 interventions. With high-certainty evidence, pimecrolimus improved 6 of 7 outcomes-among the best for 2; high-dose tacrolimus (0.1%) improved 5-among the best for 2; low-dose tacrolimus (0.03%) improved 5-among the best for 1. With moderate- to high-certainty evidence, group 5 TCS improved 6-among the best for 3; group 4 TCS and delgocitinib improved 4-among the best for 2; ruxolitinib improved 4-among the best for 1; group 1 TCS improved 3-among the best for 2. These interventions did not increase harm. Crisaborole and difamilast were intermediately effective, but with uncertain harm. Topical antibiotics alone or in combination may be among the least effective. To maintain AD control, group 5 TCS were among the most effective, followed by tacrolimus and pimecrolimus.
CONCLUSIONS: For individuals with AD, pimecrolimus, tacrolimus, and moderate-potency TCS are among the most effective in improving and maintaining multiple AD outcomes. Topical antibiotics may be among the least effective.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:152 |
|---|---|
| Enthalten in: |
The Journal of allergy and clinical immunology - 152(2023), 6 vom: 28. Dez., Seite 1493-1519 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 30.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaci.2023.08.030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361761856 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361761856 | ||
| 003 | DE-627 | ||
| 005 | 20240130232031.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaci.2023.08.030 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1275.xml |
| 035 | |a (DE-627)NLM361761856 | ||
| 035 | |a (NLM)37678572 | ||
| 035 | |a (PII)S0091-6749(23)01113-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chu, Derek K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Topical treatments for atopic dermatitis (eczema) |b Systematic review and network meta-analysis of randomized trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 30.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: Atopic dermatitis (AD) is a common skin condition with multiple topical treatment options, but uncertain comparative effects | ||
| 520 | |a OBJECTIVE: We sought to systematically synthesize the benefits and harms of AD prescription topical treatments | ||
| 520 | |a METHODS: For the 2023 American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma, and Immunology Joint Task Force on Practice Parameters AD guidelines, we searched MEDLINE, EMBASE, CENTRAL, CINAHL, LILACS, ICTRP, and GREAT databases to September 5, 2022, for randomized trials addressing AD topical treatments. Paired reviewers independently screened records, extracted data, and assessed risk of bias. Random-effects network meta-analyses addressed AD severity, itch, sleep, AD-related quality of life, flares, and harms. The Grading of Recommendations Assessment, Development and Evaluation approach informed certainty of evidence ratings. We classified topical corticosteroids (TCS) using 7 groups-group 1 being most potent. This review is registered in the Open Science Framework (https://osf.io/q5m6s) | ||
| 520 | |a RESULTS: The 219 included trials (43,123 patients) evaluated 68 interventions. With high-certainty evidence, pimecrolimus improved 6 of 7 outcomes-among the best for 2; high-dose tacrolimus (0.1%) improved 5-among the best for 2; low-dose tacrolimus (0.03%) improved 5-among the best for 1. With moderate- to high-certainty evidence, group 5 TCS improved 6-among the best for 3; group 4 TCS and delgocitinib improved 4-among the best for 2; ruxolitinib improved 4-among the best for 1; group 1 TCS improved 3-among the best for 2. These interventions did not increase harm. Crisaborole and difamilast were intermediately effective, but with uncertain harm. Topical antibiotics alone or in combination may be among the least effective. To maintain AD control, group 5 TCS were among the most effective, followed by tacrolimus and pimecrolimus | ||
| 520 | |a CONCLUSIONS: For individuals with AD, pimecrolimus, tacrolimus, and moderate-potency TCS are among the most effective in improving and maintaining multiple AD outcomes. Topical antibiotics may be among the least effective | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Atopic dermatitis (eczema) | |
| 650 | 4 | |a disease severity | |
| 650 | 4 | |a induction of remission and maintenance of remission (reactive or proactive therapy) | |
| 650 | 4 | |a network meta-analysis (comparative effects) | |
| 650 | 4 | |a patient-important outcomes (eczema severity, intensity, itch, sleep, quality of life, flares or flare-ups or exacerbations) | |
| 650 | 4 | |a topical Janus kinase (JAK) inhibitors (ruxolitinib, delgocitinib) | |
| 650 | 4 | |a topical calcineurin inhibitors (pimecrolimus, tacrolimus) | |
| 650 | 4 | |a topical corticosteroids (steroids) | |
| 650 | 4 | |a topical phosphodiesterase-4 (PDE-4) inhibitors (crisaborole, difamilast, lotamilast, roflumilast) | |
| 650 | 4 | |a topical treatments (therapy) | |
| 650 | 7 | |a pimecrolimus |2 NLM | |
| 650 | 7 | |a 7KYV510875 |2 NLM | |
| 650 | 7 | |a Tacrolimus |2 NLM | |
| 650 | 7 | |a WM0HAQ4WNM |2 NLM | |
| 650 | 7 | |a Dermatologic Agents |2 NLM | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 700 | 1 | |a Chu, Alexandro W L |e verfasserin |4 aut | |
| 700 | 1 | |a Rayner, Daniel G |e verfasserin |4 aut | |
| 700 | 1 | |a Guyatt, Gordon H |e verfasserin |4 aut | |
| 700 | 1 | |a Yepes-Nuñez, Juan José |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez-Escobar, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Herrera, Lucia C |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz Martinez, Juan Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Brignardello-Petersen, Romina |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghirad, Behnam |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Melanie M |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccacci, Renata |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Irene X |e verfasserin |4 aut | |
| 700 | 1 | |a Basmaji, John |e verfasserin |4 aut | |
| 700 | 1 | |a MacDonald, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Xiajing |e verfasserin |4 aut | |
| 700 | 1 | |a Islam, Nazmul |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Ya |e verfasserin |4 aut | |
| 700 | 1 | |a Izcovich, Ariel |e verfasserin |4 aut | |
| 700 | 1 | |a Asiniwasis, Rachel N |e verfasserin |4 aut | |
| 700 | 1 | |a Boguniewicz, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a De Benedetto, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Capozza, Korey |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Ellison, Kathy |e verfasserin |4 aut | |
| 700 | 1 | |a Frazier, Winfred T |e verfasserin |4 aut | |
| 700 | 1 | |a Greenhawt, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Huynh, Joey |e verfasserin |4 aut | |
| 700 | 1 | |a LeBovidge, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Lio, Peter A |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Stephen A |e verfasserin |4 aut | |
| 700 | 1 | |a O'Brien, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, Peck Y |e verfasserin |4 aut | |
| 700 | 1 | |a Silverberg, Jonathan I |e verfasserin |4 aut | |
| 700 | 1 | |a Spergel, Jonathan M |e verfasserin |4 aut | |
| 700 | 1 | |a Smith Begolka, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Wheeler, Kathryn E |e verfasserin |4 aut | |
| 700 | 1 | |a Gardner, Donna D |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Lynda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of allergy and clinical immunology |d 1971 |g 152(2023), 6 vom: 28. Dez., Seite 1493-1519 |w (DE-627)NLM000018449 |x 1097-6825 |7 nnns |
| 773 | 1 | 8 | |g volume:152 |g year:2023 |g number:6 |g day:28 |g month:12 |g pages:1493-1519 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaci.2023.08.030 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 152 |j 2023 |e 6 |b 28 |c 12 |h 1493-1519 | ||